Here, we have detected high levels of ERBB3 expression in EML4-ALK positive NSCLC cells after acute inhibition with LOR and subsequently, activation of PI3K/AKT signalling pathway, and we propose ERBB3 as a mechanism of LOR-treated EML4-ALK-rearragened NSCLC cells to escape from ALK-TKI inhibition. This evidence concerns the gene ALK and non-small cell lung carcinoma.